Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 951-670-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A study according OECD TG 429 was conducted to test for skin sensitizing properties in mice. Under the conditions of the present Local Lymph Node Assay, the test item tested at concentrations of 12.5 %, 25 %, 50% in a suitable vehicle (DMSO) showed no skin sensitization potential (reference 7.4.1 -1).
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 6 February 2019 - 14 February 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- 2010
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- 2008
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.2600 (Skin Sensitisation)
- Version / remarks:
- 2003
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- CBA
- Remarks:
- CaOlaHsd
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Envigo (formed partially from Harlan in September 2015), 5800 aN Venray, The Netherlands
- Females nulliparous and non-pregnant: yes
- Microbiological status of animals, when known: SPF
- Age at study initiation: 8-9 weeks
- Weight at study initiation: mean 17.8 g
- Housing: kept in groups of 5 animals in IVC cages, type II L, polysulphone cages on Altromin saw fibre bedding
- Diet: ad libitum, Altromin 1324 maintenance diet for rats and mice
- Water: ad libitum, tap water
- Acclimation period: at least five days
- Indication of any skin lesions: no
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 55 ± 10
- Air changes (per hr): at least 10 x / hour
- Photoperiod (hrs dark / hrs light): 12/12 - Vehicle:
- dimethyl sulphoxide
- Concentration:
- 12.5%, 25% and 50% (w/v), each suspended in DMSO
- No. of animals per dose:
- 5
- Details on study design:
- PRE-SCREEN TESTS:
- Compound solubility: Before the initiation of the prescreen test, a solubility test was performed to define the vehicle and the maximum concentration which is technically applicable to the animals. The maximum technically applicable concentration of the test item in the vehicle was found to be 50% (w/v) in DMSO
- Irritation:
In order to determine the highest tolerated and not excessively irritant test concentration a prescreen test was performed which was conducted under the same conditions as the main study, except there was no assessment of lymph node proliferation. The mice were observed daily for any clinical signs of systemic toxicity or local irritation at the application site. Body weights were recorded pre-test and prior to termination. Both ears were observed for erythema and scored. Ear thickness measurements were performed on day 1 (pre-dose), day 3 (approximately 48 hours after the first dose) day 6. Excessive local irritation was indicated by an erythema score > 3 and/or ear swelling of > 25%.
- Systemic toxicity: Cageside observations included spontaneous activity, lethargy, recumbent position, convulsions, tremors, apnoea, asphyxia, vocalisation, diarrhoea, changes in the skin and fur, eyes and mucous membranes (salivation, discharge).
- Ear thickness measurements: Immediately before the first application, approximately 48 hours after the first application and shortly before sacrificing the thickness of both ears of the surviving animals was measured.
- Erythema scores:
0 = No erythema
1 = Very slight erythema (barely perceptible)
2 = Well-defined erythema
3 = Moderate to severe erythema
4 = Severe erythema (beef redness) to eschar formation preventing grading of erythema
MAIN STUDY
Topical Application
Immediately before the first application the thickness of both ears of all animals was measured. Each mouse was treated by topical application of 25 µL of the selected solution to the entire dorsal surface of each ear. A second measurement of the ear thickness of all animals was carried out approximately 48 hours after the first application.Topical applications were performed once daily over three consecutive days. The first treatment day is defined as study day 1.
Administration of 3H-Methyl Thymidine
Five days after the first topical application all mice were dosed with 20 µCi 3H-methylthymidine by intravenous injection (tail vein) of 250 µL of 3H-methyl thymidine, diluted with PBS to a working concentration of 80 µCi/mL.
Preparation of Cell Suspension
Approximately 5 hours after the injection of 3H-methyl thymidine all mice were sacrificed by cervical dislocation. Shortly before sacrificing the thickness of the ears of all animals was measured for a third time. The draining auricular lymph nodes were excised, individually pooled for each animal (2 lymph nodes per animal) and collected in phosphate buffered saline (PBS). A single cell suspension of pooled lymph node cells was prepared by gentle mechanical disaggregation through polyamide gauze (200 mesh size). After washing the gauze with PBS the cell suspension was pelleted in
a centrifuge. The supernatant was discarded and the pellets were resuspended with PBS. This washing procedure was repeated. After the final wash each pellet was resuspended in approx. 1 mL 5% TCA at approx. 4 °C for approximately 18 hours for precipitation of macromolecules. Each precipitate was once washed again, resuspended in 1 mL 5% TCA and 7 mL scintillation fluid was added. Then this solution was transferred into scintillation vials and stored at room temperature overnight.
Determination of Incorporated 3H-Methyl Thymidine
The 3H-methyl thymidine - incorporation was measured in a 6-counter and expressed as the number of disintegrations per minute (DPM). Similarly, background 3H-methylthymidine levels were also measured (5% TCA). Determination of radioactivity was performed individually for each animal.
EVALUATION OF RESULTS
A substance is regarded as a 'sensitiser' in the LLNA if at least one concentration of the test item results in a 3-fold or greater increase in 3H-methyl thymidine - incorporation into lymph node cells of the test group animals, relative to that recorded for the lymph nodes of control group animals (Stimulation Index equal to or greater than 3.0). On the basis of the test results, the test substance may be classified into one of the following categories in conformity with the criteria given in Commission Regulation (EU) No 286/2011] as well as in GHS - Globally Harmonised System of Classification and Labelling of Chemicals, seventh revised edition, 2017:
Skin sensitiser
Category 1:
A substance is classified as a skin sensitiser if there is evidence in humans that the substance can lead to sensitisation by skin contact in a substantial number of persons, or if there are positive results from an appropriate animal test.
Sub-category 1A:
Substances showing a high frequency of occurrence in humans and/or a high potency in animals can be presumed to have the potential to produce significant sensitisation in humans. Severity of reaction may also be considered.
EC3 value < 2%
Sub-category 1B:
Substances showing a low to moderate frequency of occurrence in humans and/or a low to moderate potency in animals can be presumed to have the potential to produce sensitisation in humans. Severity of reaction may also be considered.
EC3 value > 2% - Positive control substance(s):
- other: 1% phenylenediamine
- Statistics:
- Grubbs, Nalimov and Dixon
- Positive control results:
- The positive-control substance exceeded the stimulation index of 3 confirming the reliability of the test system.
- Key result
- Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- test group, 12.5%
- Key result
- Parameter:
- SI
- Value:
- 1.2
- Test group / Remarks:
- test group, 25%
- Key result
- Parameter:
- SI
- Value:
- 1.4
- Test group / Remarks:
- test group, 50%
- Key result
- Parameter:
- SI
- Value:
- 10.2
- Test group / Remarks:
- positive control
- Key result
- Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- negative control
- Cellular proliferation data / Observations:
- DETAILS ON STIMULATION INDEX CALCULATION
The proliferative response of lymph node cells was expressed as the number of radioactive disintegrations per minute per lymph node (DPM/NODE) and as the ratio of 3H-methyl thymidine - incorporation into lymph node cells of test group animals relative to that recorded for control group animals (STIMULATION INDEX). Before DPM/NODE values were determined, background values were subtracted.
EC3 CALCULATION
The EC3 value (derived by linear interpolation) could not be calculated as the stimulation indices of all concentrations were below 3.
CLINICAL OBSERVATIONS:
All animals survived throughout the test period without showing any clinical signs
BODY WEIGHTS:
All animals showed the expected weight development, which allows for a weight loss of up to 2 g throughout the study. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of the present Local Lymph Node Assay, the test item tested at concentrations of 12.5 %, 25 %, 50% in a suitable vehicle (DMSO) showed no skin sensitization potential.
- Executive summary:
A study according OECD TG 429 was conducted to determine the skin sensitization potential of the test item following dermal exposure to female mice in the Local Lymph Node Assay. The vehicle and maximum dose selection was performed according to the relevant guidelines. Based on the results of a prescreen test the test item was assessed for sensitizing properties at concentrations of 12.5%, 25% and 50% (w/v), each suspended in dimethyl sulphoxide (DMSO). An appropriate positive control (1% phenylenediamine) group, furthermore a negative (vehicle DMSO) control group were employed. 3 test groups (3 different concentrations) and 1 negative control group were tested. All animals survived throughout the test period without showing any clinical signs. All animals showed the expected weight development. Directly prior to the first application, approximately 48 hours after the first application and shortly before excising the lymph nodes the thickness of both ears from all animals was measured. The means of the ear thickness per group showed no relevant difference compared to the negative control. None of the three tested concentrations of the test item reached the stimulation index of 3. The stimulation index at a concentration of 12.5% was 1.0, at a concentration of 25% the SI was 1.2 and at a concentration of 50% the SI was 1.4. The positive control substance exceeded the stimulation index of 3 confirming the reliability of the test system. Under the conditions of the Local Lymph Node Assay, the test item tested at concentrations of 50 %, 25 % and 12.5 % in a suitable vehicle (DMSO) showed no skin sensitization potential.
- Endpoint:
- skin sensitisation: in vitro
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- an in vitro skin sensitisation study does not need to be conducted because the available in vitro test methods are not applicable for the substance and therefore an in vivo skin sensitisation study was conducted
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
In vitro skin sensitization testing according OECD TG 442D and 442E was not possible since the test item was not soluble in 0.9% NaCl in water, DMSO and in tetrahydrofurane at a concentration of 1 mg/mL. Please refer to attached Statements.
Referenceopen allclose all
Table 1: Radioactive Determination of the Test Substance Groups- Main Study
POS |
CPM |
Test Item |
Conc. [%] |
Animal number |
DPM |
DPM- mean back- ground |
DPM/ Node |
Stimu- lation Index |
41 |
2079.0 |
Negative Control
|
100 |
401 |
4191.0 |
4180.0 |
2090.0 |
|
42 |
581.0 |
402 |
1171.0 |
1160.0 |
580.0 |
|
||
43 |
1241.0 |
403 |
2499.0 |
2488.0 |
1244.0 |
|
||
44 |
955.0 |
404 |
1930.0 |
1919.0 |
959.5 |
|
||
45 |
1498.0 |
405 |
3025.0 |
3014.0 |
1507.0 |
|
||
MV |
1270.8 |
MV |
2563.2 |
2552.2 |
1276.1 |
1.0 |
||
66 |
1223.0 |
Test item in DMSO |
12.5 |
1 |
|
2^22.(J |
|
10 |
67 |
1249.0 |
2 |
2516.0 |
2505.0 |
1252.5 |
1.0 |
||
68 |
950.0 |
3 |
1925.0 |
1914.0 |
957.0 |
0.7 |
||
69 |
2458.0* |
4 |
4977.0* |
n.d. |
n.d. |
n.d. |
||
70 |
1471.0 |
5 |
3001.0 |
2990.0 |
1495.0 |
1.2 |
||
MV |
1223.3 |
MV |
2493.8 |
2482.8 |
1241.4 |
1.0 |
||
SD |
184.9 |
Test item in DMSO |
SD |
381.7 |
381.7 |
190.9 |
0.1 |
|
71 |
1557.0 |
25 |
6 |
3150.0 |
3139.0 |
1569.5 |
1.2 |
|
72 |
1723.0 |
7 |
3519.0 |
3508.0 |
1754.0 |
1.4 |
||
74 |
1120.0 |
9 |
2315.0 |
2304.0 |
1152.0 |
0.9 |
||
75 |
1735.0 |
10 |
3575.0 |
3564.0 |
1782.0 |
1.4 |
||
MV |
1533.8 |
MV |
3139.8 |
3128.8 |
1564.4 |
1.2 |
||
76 |
1747.0 |
Test item in DMSO
|
50 |
11 |
3611.0 |
3600.0 |
1800.0 |
1.4 |
77 |
1275.0 |
12 |
2626.0 |
2615.0 |
1307.5 |
1.0 |
||
79 |
2113.0 |
14 |
4371.0 |
4360.0 |
2180.0 |
1.7 |
||
80 |
2512.0 |
15 |
5156.0 |
5145.0 |
2572.5 |
2.0 |
||
MV |
1716.2 |
MV |
3538.0 |
3527.0 |
1763.5 |
1.4 |
||
SD |
565.4 |
SD |
1161.7 |
1161.7 |
580.8 |
0.5 |
||
96 |
4.0 |
Background Szinti and TCA
|
|
|
8.0 |
|
|
|
97 |
5.0 |
|
9.0 |
|
|
|
||
98 |
7.0 |
|
14.0 |
|
|
|
||
99 |
6.0 |
|
13.0 |
|
|
|
||
100 |
5.0 |
MV |
11.0 |
0.0 |
0.0 |
0.0 |
||
SD |
1.0 |
SD |
2.3 |
|
|
|
POS
= position in counter; CPM = counts per minute; Conc. = concentration
DPM = disintegrations per minute;
*
= outlier; failed Grubbs, Nalimov and Dixon; ** = outlier, failed
Nalimov; n.d. = not determined
MV = mean value; SD = standard deviation; Szinti = scintillation fluid;
TCA = trichloroacetic acid
If not noted individually, the results include both lymph nodes of an animal.
Table 2: Radioactive Determination of the accompanying Positive control group
POS |
CPM |
Test Item |
Conc. [%] |
Animal number |
DPM |
DPM- mean back- ground |
DPM/ Node |
Stimu- lation Index |
41 |
2079.0 |
Negative Control
|
|
401 |
4191.0 |
4180.0 |
2090.0 |
|
42 |
581.0 |
|
402 |
1171.0 |
1160.0 |
580.0 |
|
|
43 |
1241.0 |
|
403 |
2499.0 |
2488.0 |
1244.0 |
|
|
44 |
955.0 |
100 |
404 |
1930.0 |
1919.0 |
959.5 |
|
|
45 |
1498.0 |
|
405 |
3025.0 |
3014.0 |
1507.0 |
|
|
MV |
1270.8 |
|
MV |
2563.2 |
2552.2 |
1276.1 |
1.0 |
|
SD |
506.2 |
|
SD |
1020.4 |
1020.4 |
510.2 |
|
|
46 |
15594.0 |
Positive Control
|
|
406 |
31565.0 |
31554.0 |
15777.0 |
12.4 |
47 |
13068.0 |
1 |
407 |
26559.0 |
26548.0 |
13274.0 |
10.4 |
|
50 |
8683.0 |
|
410 |
17768.0 |
17757.0 |
8878.5 |
7.0 |
|
MV |
13099.6 |
|
MV |
26633.4 |
26622.4 |
13311.2 |
10.4 |
|
SD |
2529.7 |
|
SD |
5106.9 |
5106.9 |
2553.5 |
2.0 |
|
96 |
4.0 |
Background Szinti and |
|
|
8.0 |
|
|
|
97 |
5.0 |
|
|
9.0 |
|
|
|
|
98 |
7.0 |
|
|
14.0 |
|
|
|
|
MV |
5.4 |
|
MV |
11.0 |
0.0 |
0.0 |
0.0 |
|
SD |
1.0 |
|
SD |
2.3 |
|
|
|
POS =
position in counter; CPM = counts per minute; Conc. = concentration;
DPM = disintegrations per minute;
MV = mean value; SD = standard deviation; Szinti = scintillation fluid; TCA = trichloroacetic acid
If not noted individually, the results include both lymph nodes of an animal.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
In vitro skin sensitization testing according OECD TG 442D and 442E was not possible since the test item was not soluble in 0.9% NaCl in water, DMSO and in tetrahydrofurane at a concentration of 1 mg/mL.
Therefore, a study according OECD TG 429 was conducted to determine the skin sensitization potential of the test item following dermal exposure to female mice in the Local Lymph Node Assay. The vehicle and maximum dose selection was performed according to the relevant guidelines. Based on the results of a prescreen test the test item was assessed for sensitizing properties at concentrations of 12.5%, 25% and 50% (w/v), each suspended in dimethyl sulphoxide (DMSO). An appropriate positive control (1% phenylenediamine) group, furthermore a negative (vehicle DMSO) control group were employed. 3 test groups (3 different concentrations) and 1 negative control group were tested. All animals survived throughout the test period without showing any clinical signs. All animals showed the expected weight development. Directly prior to the first application, approximately 48 hours after the first application and shortly before excising the lymph nodes the thickness of both ears from all animals was measured. The means of the ear thickness per group showed no relevant difference compared to the negative control. None of the three tested concentrations of the test item reached the stimulation index of 3. The stimulation index at a concentration of 12.5% was 1.0, at a concentration of 25% the SI was 1.2 and at a concentration of 50% the SI was 1.4. The positive control substance exceeded the stimulation index of 3 confirming the reliability of the test system. Under the conditions of the Local Lymph Node Assay, the test item tested at concentrations of 50 %, 25 % and 12.5 % in a suitable vehicle (DMSO) showed no skin sensitization potential (reference 7.4.1 -1).
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Classification, Labeling, and Packaging Regulation (EC) No 1272/2008
The available test data are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008. Based on this information, the substance is not considered to be classified for skin sensitisation under Regulation (EC) No 1272/2008, as amended for the twelfth time in Regulation (EU) 2019/521.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.